Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
-
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
-
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
-
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
-
BARCELONA, Spain and CAMBRIDGE, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
-
BARCELONA, Spain and CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop...
-
BARCELONA, Spain and CAMBRIDGE, Mass., Dec. 30, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics – ORY (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
-
BARCELONA, Spain and CAMBRIDGE, Mass., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics - ORY (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
-
Company valued at approximately EUR 100 million Priced at EUR 3.39 per share Founders, Carlos Buesa and Tamara Maes, control 26.3% of shares outstanding BARCELONA,...
-
BARCELONA, Spain and CAMBRIDGE, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and...